{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:07:05Z","timestamp":1790784425468,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Lupus nephritis (LN) remains a major cause of morbidity among patients with systemic lupus erythematosus, and treatment resistance continues to pose clinical challenges. Calcineurin inhibitors (CNIs), including tacrolimus (TAC) and voclosporin (VCS), are used in induction regimens, but randomized evidence for the two agents arises from clinically different trial designs. This systematic review and meta-analysis separately quantifies randomized evidence for TAC-based and VCS-based induction regimens. Methods: Following PRISMA guidance, the literature search was updated to September 2026. Eligible studies were randomized controlled trials enrolling adults with biopsy-proven active class III, IV, or V LN and were required to report complete and\/or partial renal-response data in a form permitting extraction or calculation of an effect estimate. Study inclusion was not based on whether the treatment effect was favorable or statistically significant. Complete renal response was the prespecified primary outcome for quantitative synthesis. Separate random-effects meta-analyses were performed for TAC-based and VCS-based regimens. Because the two evidence sets did not share a sufficiently comparable common comparator, no formal TAC-versus-VCS Bucher comparison was retained. Results: Five randomized controlled trials were included in the quantitative synthesis: three TAC trials and two VCS trials. TAC-based regimens increased complete renal response relative to their respective comparators (RR, 1.36; 95% CI, 1.00\u20131.86), although heterogeneity was substantial (I2 = 73%) and sensitivity analyses showed that the pooled result was influenced by the multitarget TAC + MMF trial. VCS added to MMF and low-dose glucocorticoids increased complete renal response versus the placebo with the same background therapy (RR, 1.78; 95% CI, 1.35\u20132.34; I2 = 0%). Safety outcomes were summarized descriptively because definitions and reporting differed across trials. Conclusions: TAC-based and VCS-based induction regimens each showed benefits within their respective randomized trial settings. Differences in background therapy, comparators, study populations, and outcome definitions preclude a reliable indirect efficacy comparison between TAC and VCS. Head-to-head randomized trials using standardized background therapy and outcomes are needed.<\/jats:p>","DOI":"10.3390\/jcm15197607","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:20:59Z","timestamp":1790781659000},"page":"7607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Tacrolimus and Voclosporin as Induction Therapy in Lupus Nephritis: A Focused Systematic Review and Meta-Analysis of Randomized Evidence"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-9928","authenticated-orcid":false,"given":"Urvi","family":"Zala","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Loyola Medicine MacNeal Hospital, Berwyn, IL 60402, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-4441","authenticated-orcid":false,"given":"Rushi","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3874-1197","authenticated-orcid":false,"given":"Jacob","family":"Thompson","sequence":"additional","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Anil","family":"Regmi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Parkview Health, Fort Wayne, IN 46845, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","article-title":"Lupus nephritis: Clinical presentations and outcomes in the 21st century","volume":"59","author":"Gasparotto","year":"2020","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41581-023-00722-z","article-title":"Pathogenic cellular and molecular mediators in lupus nephritis","volume":"19","author":"Mohan","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jalm\/jfac036","article-title":"A review of lupus nephritis","volume":"7","author":"Alforaih","year":"2022","journal-title":"J. Appl. Lab. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: Consensus, evidence, and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","first-page":"1408","article-title":"Impact of glucocorticoid dose on outcomes during initial therapy of lupus nephritis","volume":"76","author":"Prokop","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e22328","DOI":"10.1097\/MD.0000000000022328","article-title":"Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in lupus nephritis induction","volume":"99","author":"Jiang","year":"2020","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8345737","DOI":"10.1155\/2022\/8345737","article-title":"Revisited cyclophosphamide in the treatment of lupus nephritis","volume":"2022","author":"Quan","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.13761119","article-title":"The evolving role of calcineurin inhibitors in treating lupus nephritis","volume":"15","author":"Peleg","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, M., Zhou, J., Niu, Q., and Wang, H. (2024). Mechanism of tacrolimus in the treatment of lupus nephritis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1331800"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.191008","article-title":"Long-term safety and effectiveness of tacrolimus in lupus nephritis","volume":"48","author":"Takeuchi","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17512433.2022.2092470","article-title":"Voclosporin: A novel calcineurin inhibitor for lupus nephritis","volume":"15","author":"Lerma","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kale, A., Shelke, V., Lei, Y., Gaikwad, A.B., and Anders, H.J. (2023). Voclosporin: Chemistry, pharmacology, and toxicity profile. Cells, 12.","DOI":"10.3390\/cells12202440"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Long-term voclosporin treatment in lupus nephritis (AURORA 2)","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis","volume":"162","author":"Liu","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e224492","DOI":"10.1001\/jamanetworkopen.2022.4492","article-title":"Tacrolimus vs cyclophosphamide for lupus nephritis","volume":"5","author":"Zheng","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Chapter 13: Assessing risk of bias due to missing results in a synthesis. Cochrane Handbook for Systematic Reviews of Interventions, Wiley-Blackwell. [2nd ed.].","DOI":"10.1002\/9781119536604"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/09612033251361560","article-title":"Comparative Efficacy of Intravenous Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus as Induction Therapy for Lupus Nephritis: A Randomized Controlled Open-Label Trial; (Excluded from this review because eligibility allowed age \u2265 10 years and clinical or biopsy-proven LN)","volume":"34","author":"Amudalapalli","year":"2025","journal-title":"Lupus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/TP.0000000000003350","article-title":"Thirty years of tacrolimus in clinical practice","volume":"105","author":"Ong","year":"2021","journal-title":"Transplantation"},{"key":"ref_26","first-page":"1241","article-title":"Clinical pharmacokinetics and pharmacodynamics of voclosporin","volume":"62","author":"Keller","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ponticelli, C., Reggiani, F., and Moroni, G. (2021). Old and new calcineurin inhibitors in lupus nephritis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214832"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40620-020-00757-6","article-title":"Calcineurin inhibitors in lupus nephritis","volume":"34","author":"Ponticelli","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_29","first-page":"e21905","article-title":"Tacrolimus ameliorates podocyte injury via FKBP12 restoration","volume":"35","author":"Yasuda","year":"2021","journal-title":"FASEB J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2215\/CJN.0000000000000297","article-title":"Efficacy of voclosporin in proliferative lupus nephritis","volume":"19","author":"Hodge","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"110180","DOI":"10.1016\/j.clim.2024.110180","article-title":"The role of podocytes in lupus nephritis","volume":"262","author":"Ichinose","year":"2024","journal-title":"Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13091","DOI":"10.3892\/mmr.2023.13091","article-title":"Immune podocytes in lupus nephritis","volume":"28","author":"Liu","year":"2023","journal-title":"Mol. Med. Rep."},{"key":"ref_33","first-page":"83","article-title":"Pharmacokinetic differences between cyclosporine and voclosporin","volume":"12","author":"Li","year":"2020","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-021-01488-z","article-title":"Voclosporin: First approval","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e42858","DOI":"10.1097\/MD.0000000000042858","article-title":"Voclosporin in systemic lupus erythematosus","volume":"104","author":"Ashinze","year":"2025","journal-title":"Medicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:25:11Z","timestamp":1790781911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":36,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197607"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197607","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}